| Oct 9 |
Accelerate Diagnostics Inc (AXDX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...
|
| Oct 1 |
Accelerate Diagnostics Stock Down Despite FDA Clearance for Arc System
|
| Oct 1 |
FDA approves Accelerate Arc system to identify microbial infections
|
| Sep 30 |
Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System
|
| Aug 10 |
Accelerate Diagnostics, Inc. (AXDX) Q2 2024 Earnings Call Transcript
|
| Aug 8 |
Accelerate Diagnostics GAAP EPS of -$0.50 beats by $0.05, revenue of $3M in-line
|
| Aug 8 |
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
|
| Aug 8 |
Accelerate Diagnostics: Q2 Earnings Snapshot
|
| Aug 8 |
Accelerate Diagnostics Reports Second Quarter 2024 Financial Results
|
| Aug 8 |
Accelerate Diagnostics Announces a Successful Completion of its WAVE™ Pre-Clinical Trial
|
